Cancer is still one of the main causes of death in the world. Many research is focused on the development of new diagnostics and treatments. We investigate the potential use of innovative diagnostic tools, like imaging, drug monitoring, biomarkers and genetics, to select patients before start of their potential therapy and to personalize and evaluate treatments. This approach results in more effective and less toxic treatment for cancer patients.
Furthermore we study the development, manufacturing and potential use of new innovative drugs. We are especially interested in Advanced Medicinal Products like engineered monoclonal antibodies, vaccines and gen/cell therapy. At this moment we are working, together with the department of hematology, on the point-of-care development, production and use of CAR T-cells in patients with B-cell lymphoma. This approach is hypothesized to be equally effective with less costs compared to the commercial available product.